Flu vaccination campaign poses monitoring difficulties

Collier, Roger
October 2009
CMAJ: Canadian Medical Association Journal;10/13/2009, Vol. 181 Issue 8, pE163
Academic Journal
The article offers information on the monitoring difficulties posed by the Flu vaccination campaign. According to the provincial health officer for British Columbia Dr. Perry Kendall, H1N1 infection is a complicate matters as few people will have H1N1 infections by getting the vaccine or few will be infected after getting the vaccine. He also added that the vaccine must be delivered before the virus or bacteria which is trying to protect against is in the community.


Related Articles

  • Incidence of Adverse Events Among Healthcare Workers Following H1N1 Mass Immunization in Ghana. Ankrah, Daniel; Mantel-Teeuwisse, Aukje; Bruin, Marie; Amoo, Philip; Ofei-Palm, Charles; Agyepong, Irene; Leufkens, Hubert // Drug Safety;2013, Vol. 36 Issue 4, p259 

    Background: Cases of the A(H1N1) 2009 influenza were first recorded in Ghana in July 2009. In June 2010 when prioritized vaccination against the novel A(H1N1) 2009 influenza virus started in the country, health workers were among the selected groups to receive the vaccination. Objective: The aim...

  • Pandemic Influenza H1N1 Vaccination Intention in the Post-Pandemic Phase: Psychosocial Determinants and Implications from a 2010 National Survey in Taiwan. Jiun-Hau Huang; Pei-Chun Kuo; Yen-Yu Miao // International Proceedings of Economics Development & Research;2012, Vol. 40, p87 

    Background: Vaccination has been recommended as one of the most effective ways to protect people from severe illness during influenza pandemics; however, little is known about the acceptability and psychosocial determinants of intention to receive vaccination against pandemic influenza A/H1N1...

  • MIELITIS TRANSVERSA RELACIONADA CON VACUNACION ANTI-INFLUENZA A (H1N1). Arcondo, Maria Florencia; Wachs, Adolfo; Zylberman, Marcelo // Medicina (Buenos Aires);2011, Vol. 71 Issue 2, p161 

    Transverse myelitis is an inflammatory disorder characterized by spinal cord dysfunction. Infectious, autoimmune, postinfectious and postvaccination diseases are the most common recognized causes of transverse myelitis, but near 50% of the cases are finally assumed as idiopathic. Rubeolla,...

  • Models cannot predict future outbreaks: A/H1N1 virus, the paradigm. Nougairède, Antoine; Charrel, Rémi; Raoult, Didier // European Journal of Epidemiology; 

    Evolution of the industrialized society had led to a risk management policy in many domains. Assessment of health care risk in the case of infectious diseases often includes mathematical models. Results of modelling were used in France to design emergency plans against flu pandemic. We believe...

  • Effectiveness of an Adjuvanted Monovalent Vaccine Against the 2009 Pandemic Strain of Influenza A(H1N1)v, in Stockholm County, Sweden. Örtqvist, Åke; Berggren, Ingela; Insulander, Mona; de Jong, Birgitta; Svenungsson, Bo // Clinical Infectious Diseases;May2011, Vol. 52 Issue 10, p1203 

    A population-based cohort study, including approximately one million vaccinated and one million non-vaccinated persons, demonstrating that a monovalent AS03-adjuvanted influenza-vaccine was 87%-95% effective during the peak of the pandemic in prevention of influenza A(H1N1)v in Stockholm County,...

  • Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals. Lagler, Heimo; Grabmeier-Pfistershammer, Katharina; Touzeau-Römer, Veronique; Tobudic, Selma; Ramharter, Michael; Wenisch, Judith; Gualdoni, Guido André s; Redlberger-Fritz, Monika; Popow-Kraupp, Theresia; Rieger, Armin; Burgmann, Heinz // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Background: During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine CelvapanH (Baxter) was used in Austria. CelvapanH is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this...

  • Comparison of a Live Attenuated 2009 H1N1 Vaccine with Seasonal Influenza Vaccines against 2009 Pandemic H1N1 Virus Infection in Mice and Ferrets. Chen, Grace L.; Min, Ji-Young; Lamirande, Elaine W.; Santos, Celia; Jin, Hong; Kemble, George; Subbarao, Kanta // Journal of Infectious Diseases;Apr2011, Vol. 203 Issue 7, p930 

    The role of seasonal influenza vaccination in pandemic influenza A H1N1 disease is important to address, because a large segment of the population is vaccinated annually. We administered 1 or 2 doses of pandemic H1N1 vaccine (CA/7 ca), a seasonal trivalent inactivated (s-TIV), or live attenuated...

  • Influenza A (H1N1) 2009 Vaccine, Inactivated.  // AHFS Consumer Medication Information;Oct2017, p1 

    What is 2009 H1N1 influenza? How is 2009 H1N1 different from regular (seasonal) flu? 2009 H1N1 influenza vaccine Who should get 2009 H1N1 influenza vaccine and when? Some people should not get the vaccine or should wait What are the risks from 2009 H1N1 influenza vaccine? What if there is a...

  • Influenza A (H1N1) 2009 Vaccine, Live Intranasal.  // AHFS Consumer Medication Information;Oct2017, p1 

    What is 2009 H1N1 influenza? How is 2009 H1N1 different from regular (seasonal) flu? 2009 H1N1 influenza vaccine Who should get 2009 H1N1 influenza vaccine and when? Some people should not get the vaccine or should wait What are the risks from 2009 H1N1 LAIV? What if there is a severe reaction?...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics